AbbVie Signs a Worldwide Non-Exclusive License Agreement for Humira’s (adalimumab) Patent Rights with Pfizer

Shots:

• Pfizer to get worldwide IPR for Humira in the US and other countries and will pay royalties on sales to AbbVie
• Humira’s the US license right will begin from 20 Nov, 2023 and will be available in EU post EMA approval
• Humira (adalimumab) a mAb helps in blocking TNF protein, approved for 14 global indications and 10 the US indications

Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie